ALX Oncology Holdings Inc. (ALXO) Fundamentals

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
SHARE INFORMATION
Market Cap$ 325,447,576
Shares Outstanding40,680,947
Float21,274,118
Percent Float52.3%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -2.06
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions344
Institutional Holdings Date2022-05-31
Institutional Bought Previous 3 Months4,456,732
Institutional Holdings Percent139.6%
Institutional Sold Previous 3 Months3,130,795
Insider Holdings Date2022-05-31
Insider Bought Previous 3 Months-
Insider Holdings Percent2.1
Insider Sold Previous 3 Months-
Insider Shares Owned845,523
TRADING INFO
52 Week High$ 81.19
52 Week Low$ 5.82
52 Week High Change$ -85.49
21 Day Moving Average$ 7.2669
21 Day Extended Moving Average$ 7.5847
50 Day Moving Average$ 9.9731
50 Day Extended Moving Average$ 9.8846
200 Day Moving Average$ 28.4443
200 Day Extended Moving Average$ 25.892
10 Day Average Volume1,040,860
20 Day Average Volume764,268
30 Day Average Volume643,652
50 Day Average Volume530,446
Alpha-0.061850
Beta2.7283
Standard Deviation0.284842
R20.201618
7 Day Price Change$ 1.53
7 Day Percent Change23.65%
21 Day Price Change$ 0.40
21 Day Percent Change5.26%
30 Day Price Change$ 0.25
30 Day Percent Change3.23%
Month to Date Price Change$ 0.33
Month to Date Percent Change4.3%
Quarter to Date Price Change$ -8.90
Quarter to Date Percent Change-52.66%
180 Day Price Change$ -15.26
180 Day Percent Change-65.61%
200 Day Price Change$ -23.56
200 Day Percent Change-74.65%
Year to Date Price Change$ -13.49
Year to Date Percent Change-62.77%

ALX Oncology Holdings Inc. (ALXO) Key Ratios

PROFITABILITY
EBIT Margin-10,177.4%
EBITDA Margin-10,159.6%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin9.1%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.00
Total Debt To Equity0.00
Int Coverage-9,382.20
Current Ratio21.00
Leverage Ratio1.00
Quick Ratio20.70
Long Term Debt To Capital0.01
VALUATION MEASURES
PE Ratio-3.50
Enterprise Value$ 9,876,576
Price to Sales0.00
Price to Free Cash-3.70
PE High Last 5 Years0.00
Price To Book1.00
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book1.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-23.55
Return on Equity-24.62
Return on Capital-24.58

ALX Oncology Holdings Inc. (ALXO) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorKPMG LLP
CEOJaume Pons
Emplyoees44
Last AuditUE
CIK0001810182
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address323 Allerton Avenue
Suite 100
South San Francisco, CA 94080
Websitehttps://www.alxoncology.com
Facsimile-
Telephone+1 650 466-7125
Email-


Your Recent History
NASDAQ
ALXO
ALX Oncolo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.